Supernormal Oxygen Delivery for Patients With Severe Burns
NCT ID: NCT05241912
Last Updated: 2022-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
100 participants
INTERVENTIONAL
2022-02-28
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Goal-directed Hemodynamic Therapy on Short-term Postoperative Complications in Patients With Extensive Burns
NCT05221788
Retrospective Analysis of Spray Skin Treats for Severe Burns
NCT06170424
Research on the Key Technology of Burn Wound Treatment
NCT03279549
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
NCT04090424
A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)
NCT06440239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
No interventions assigned to this group
Goal-directed fluid group
Intervention: administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia.
Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution.
Dobutamine
administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dobutamine
administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangzhou Red Cross Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liang Bing
Associate senior doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangzhou Red cross hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-005-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.